Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00858702|
Recruitment Status : Completed
First Posted : March 10, 2009
Results First Posted : August 26, 2009
Last Update Posted : October 11, 2017
Daiichi Sankyo Co., Ltd.
Information provided by:
Daiichi Sankyo, Inc.
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Drug: olmesartan medoxomil and a CCB
Drug: olmesartan medoxomil and a diuretic
|Recruitment Details||A total of 172 patients were enrolled at 5 centers in Japan from February 12, 2005 to April 30, 2005.|
|Pre-assignment Details||After the 4 to 6 weeks of olmesartan medoxomil monotherapy period, 105 patients who met the entry criteria for the combination therapy period were randomized to calcium channel blocker (of the dihydropyridine class) combination group or diuretic (of the thiazide class)combination group.|
No Adverse Events Reported